Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Merck & Co., Inc. : Hundreds of Fosamax lawsuits versus Merck ordered readied for trial

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/30/2013 | 10:53pm CEST

A federal judge overseeing consolidated litigation against Merck & Co over jaw injuries allegedly caused by the osteoporosis drug Fosamax has ordered hundreds of cases be dispersed to courts across the country for trial.

The decision by U.S. District Judge John Keenan in Manhattan marks an unusual and potentially costly development for Merck.

Companies often find it easier to reach settlements in mass tort cases that are consolidated before one judge.

"It's a big deal as it changes the cost paradigm for Merck exponentially," said Timothy O'Brien, a partner at Levin, Papantonio, Thomas, Mitchell, Rafferty & Proctor and lawyer representing Fosamax plaintiffs.

The judge's order Thursday requires that 200 cases per month be sent to back to courts where they were initially filed, beginning with the oldest ones.

Lainie Keller, a spokeswoman for Merck, said the company "is committed to defending its conduct in regard to Fosamax and has confidence in its defense strategy that has had so much success in the courts."

The cases before Keenan comprised roughly one-fifth of the 5,075 lawsuits pending nationally in federal and state courts related to Fosamax, a one-time blockbuster medication.

Lawsuits alleging that plaintiffs developed osteonecrosis of the jaw from Fosamax were consolidated before Keenan in 2006.

The judge conducted a series of "bellwether" trials, allowing the parties to assess trends and outcomes in similar cases. A series of wins for plaintiffs, for example, can put them in a better position for settlement talks.

The final Fosamax bellwether trial before Keenan ended in February with a $285,000 verdict for plaintiff Rhoda Scheinberg.

Merck lost just one other of the five bellwether trials before Keenan, when a jury in 2010 awarded Florida resident Shirley Boles $8 million, a sum the judge reduced to $1.5 million.

Keenan's order on Friday came after mediation to resolve 370 cases broke down two weeks ago. O'Brien's law firm and another firm represented plaintiffs in those cases.

Another 104 lawsuits brought by another firm could have been added to the talks if a deal on value was reached, O'Brien said.

Lawyers for the plaintiffs had sought to have 300 cases transferred every four months, while Merck sought to have just 100 cases scheduled for discovery over a six-month period.

Merck has benefited from having the litigation consolidated.

Keenan had thrown out 430 cases after he issued an order last November, which Merck had sought, requiring them to put forth expert reports showing scientific proof of their claims.

But in his order Friday, Keenan said Merck's latest proposal would "unnecessarily prolong" the proceedings before him.

Keenan ordered plaintiffs to recommend by October 11 where to sent the first batch of cases.

An order moving so many personal injury cases home at once is rare, O'Brien said. He noted that Merck reached a $4.85 billion settlement with over the painkiller Vioxx in 2007 only after a federal judge threatened a similar order.

"I anticipate Merck will continue talking and seek to resolve the cases," O'Brien said. "The opportunity is there."

The case is In Re Fosamax Products Liability Litigation, U.S. District Court, Southern District of New York, No. 06-md-01789.

(Reporting by Nate Raymond in New York; Editing by Bernard Orr)

By Nate Raymond

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
07/21 MERCK AND : European Medicines Agency’s CHMP Recommends Approval for Merck..
07/21 Merck, Pfizer Collaborate With Corning
07/20 MERCK AND : Pfizer Collaborate with Corning to Modernize Pharmaceutical Glass Pa..
07/20 Merck and Pfizer Collaborate with Corning to Modernize Pharmaceutical Glass ..
07/20 MERCK : Announces U.S. FDA Grants Tentative Approval for LUSDUNA™ Nexvue&t..
07/18 COMPANHIA BRASILEIRA DE DISTRIBUICAO : (CBD) EPS Estimated At $0.06, Merck & Com..
07/17 MERCK : Announces Presentations of Clinical and Real-World Data at The Alzheimer..
07/12 NETSCIENTIFIC : portfolio company in cancer clinical trial with US drugs giant M..
07/11 MERCK AND : Global Biologic Response Modifiers Sales Market 2017 by top Players ..
07/11 NETSCIENTIFIC : Portfolio Firm Inks Clinical Trial Agreement With Merck
More news
News from SeekingAlpha
07/22 Stocks to watch next week
07/22 3 THINGS IN BIOTECH YOU SHOULD LEARN : July 22, 2017
07/21 European advisory group backs approval of 11 new meds
07/21 WALL STREET BREAKFAST : Confidence In Bitcoin Is Back
07/20 Gilead Has Another Ace Up Its Sleeve
Financials ($)
Sales 2017 40 068 M
EBIT 2017 13 716 M
Net income 2017 7 101 M
Debt 2017 5 068 M
Yield 2017 3,00%
P/E ratio 2017 23,30
P/E ratio 2018 18,14
EV / Sales 2017 4,40x
EV / Sales 2018 4,24x
Capitalization 171 303 M
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 69,7 $
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY6.39%171 303
JOHNSON & JOHNSON17.45%364 503
ROCHE HOLDING LTD.4.90%221 492
NOVARTIS8.37%220 936
PFIZER3.08%199 378
SANOFI6.01%119 827